大洋洲 · 综合新闻 · The Mercury
Neurizon advances Regimen I into treatment extension alongside $3.7m R&D drawdown
详细摘要
The first participant in Regimen I of Neurizon Therapeutics’ Phase 2/3 ALS Platform Trial has completed the 36-week randomised controlled trial (RCT) phase and transitioned into…
MarketNews 仅展示媒体发布的标题和摘要,全文请在出版方网站阅读。 (www.themercury.com.au)


